News | February 18, 2022
Ligand posts strong 2021 performance
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
She holds a Masters degree in Genetics along with a Ph.D. in Biochemistry
The first patient in India treated at Jaslok Hospital and Research Centre, Mumbai Includes the world’s smallest implantable spinal cord stimulator
Dr. Reddy’s to promote and distribute select Novartis products including the Voveran range, the Calcium range and Methergine in India
It will showcase the company’s latest technologies in robotics, digital health and orthopaedic implants
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Subscribe To Our Newsletter & Stay Updated
